Targeted treatment of pruritus: A look into the future

H. L. Tey, Gil Yosipovitch

Research output: Contribution to journalReview article

54 Citations (Scopus)

Abstract

Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease-activated receptor 2, serine proteases, cathepsin S, peripheral mu- and kappa-opioid receptors, interleukin-31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas-related G protein-coupled receptors. In the spinal cord, gastrin-related peptide and its receptor, as well as substance P and its receptor neurokinin receptor-1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito-affective aspects of the disease.

Original languageEnglish (US)
Pages (from-to)5-17
Number of pages13
JournalBritish Journal of Dermatology
Volume165
Issue number1
DOIs
StatePublished - Jul 1 2011
Externally publishedYes

Fingerprint

Pruritus
Neurokinin-1 Receptors
cathepsin S
PAR-2 Receptor
Central Nervous System Sensitization
Nerve Growth Factor Receptor
Histamine Receptors
kappa Opioid Receptor
Skin
Peptide Receptors
mu Opioid Receptor
Interleukins
Gyrus Cinguli
Gastrins
Serine Proteases
Peripheral Nervous System Diseases
G-Protein-Coupled Receptors
Peripheral Nerves
Acetylcholine
Spinal Cord

ASJC Scopus subject areas

  • Dermatology

Cite this

Targeted treatment of pruritus : A look into the future. / Tey, H. L.; Yosipovitch, Gil.

In: British Journal of Dermatology, Vol. 165, No. 1, 01.07.2011, p. 5-17.

Research output: Contribution to journalReview article

@article{5c6066f7d4e94f41b786f09e7a33d294,
title = "Targeted treatment of pruritus: A look into the future",
abstract = "Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease-activated receptor 2, serine proteases, cathepsin S, peripheral mu- and kappa-opioid receptors, interleukin-31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas-related G protein-coupled receptors. In the spinal cord, gastrin-related peptide and its receptor, as well as substance P and its receptor neurokinin receptor-1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito-affective aspects of the disease.",
author = "Tey, {H. L.} and Gil Yosipovitch",
year = "2011",
month = "7",
day = "1",
doi = "10.1111/j.1365-2133.2011.10217.x",
language = "English (US)",
volume = "165",
pages = "5--17",
journal = "British Journal of Dermatology",
issn = "0007-0963",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Targeted treatment of pruritus

T2 - A look into the future

AU - Tey, H. L.

AU - Yosipovitch, Gil

PY - 2011/7/1

Y1 - 2011/7/1

N2 - Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease-activated receptor 2, serine proteases, cathepsin S, peripheral mu- and kappa-opioid receptors, interleukin-31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas-related G protein-coupled receptors. In the spinal cord, gastrin-related peptide and its receptor, as well as substance P and its receptor neurokinin receptor-1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito-affective aspects of the disease.

AB - Recent advances in pruritus research have elucidated mediators and neuronal pathways involved in itch transmission, and this fast emerging knowledge may possibly be translated into new therapies in the near future. In the skin and peripheral nerves, potential mediator and receptor therapeutic targets include the H4 histamine receptor, protease-activated receptor 2, serine proteases, cathepsin S, peripheral mu- and kappa-opioid receptors, interleukin-31, transient receptor potential vanilloid 1 and 3, fatty acid amide hydrolase, nerve growth factor and its receptor, acetylcholine, and the Mas-related G protein-coupled receptors. In the spinal cord, gastrin-related peptide and its receptor, as well as substance P and its receptor neurokinin receptor-1 serve as potential therapeutic targets. In the brain, reduction of itch perception and modulation of emotions may possibly be achieved through drugs acting on the anterior cingulate cortex. Clinically, management of pruritus should be instituted early and should address the skin pathology, peripheral neuropathy, central sensitization, and the cognito-affective aspects of the disease.

UR - http://www.scopus.com/inward/record.url?scp=79959759852&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959759852&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2133.2011.10217.x

DO - 10.1111/j.1365-2133.2011.10217.x

M3 - Review article

C2 - 21219293

AN - SCOPUS:79959759852

VL - 165

SP - 5

EP - 17

JO - British Journal of Dermatology

JF - British Journal of Dermatology

SN - 0007-0963

IS - 1

ER -